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Abstract: Lipocalin-2 (LCN2) is a 25-kDa protein in the lipocalin family that shows antibacterial activity. The aim of this study
was to clone human LCN2 into the mammalian-specific pIRES2-AcGFP1 vector and to determine the antibacterial activity of the
recombinant pIRES2-AcGFP1-hLCN2 plasmid against major bacterial pathogens that cause bovine mastitis. The amplified hLCN2 was
successfully cloned into the vector, and the plasmid was transfected into bovine mammary epithelial stem cells using nucleofection.
Immunochemistry, reverse transcription polymerase chain reaction, and ELISA were used to monitor and quantify hLCN2 expression
in the cells. After 1 day of incubation, the concentration of hLCN2 secreted by cells in the medium (6.85 ± 0.11 µg) was higher than that
stored within the cells (22 ± 2.52 ng). After 4 days of culture, the amount of hLCN2 was 300-fold higher in the medium than within the
cells. The recombinant clone showed potential antibacterial activity against mastitis-causing bacteria, with greater inhibitory activity
against Escherichia coli than against Staphylococcus aureus. Antibacterial activity remained strong after 4–5 h of culture. Thus, pIRES2AcGFP1 was identified as an efficient vector for the delivery of the target gene to the mammary cells, and recombinant hLCN2 showed
strong antibacterial activity against major mastitis-causing bacteria.
Key words: Recombinant human lipocalin 2, pIRES2 vector, transfection, bovine mammary epithelial stem cells, antibacterial, bovine
mastitis

1. Introduction
Lipocalin-2 (LCN2, also known as neutrophil gelatinaseassociated lipocalin) belongs to the lipocalin protein family.
The members of this family have a barrel-shaped tertiary
structure containing a hydrophobic pocket that can bind
lipophilic molecules (Flower, 1994). The human lipocalin-2
gene (hLCN2) is located at the human chromosomal 9q34
location. LCN2 was initially discovered in the granules of
human neutrophils (Xu and Venge, 2000) and was later
shown to be expressed during inflammatory responses by
certain epithelial cells (Cowland et al., 2003).
Iron is required for many essential life processes.
However, excess free iron can injure cells and increase
their susceptibility to bacterial infections by promoting
hydroxyl radical production (Smith, 2007). Siderophores
are chelators with a high affinity for iron that are utilized
by bacteria to absorb iron, thereby enabling the bacteria to
survive in the host (Flo et al., 2004; Raffatellu et al., 2009).
These proteins are also part of the innate immune defense
system (Smith, 2007) and are released by microorganisms
* Correspondence: newdkjeong@gmail.com

when the lack of soluble iron becomes a limiting factor for
growth.
LCN2 binds to bacterial siderophores, depriving
bacteria of iron; thus, LCN2 acts as a bacteriostatic protein.
LCN2 was highly expressed during acute microbial
infection and during tissue involution (Miharada et al.,
2005). LCN2 protein levels are increased in blood serum
during infection and inflammation (Berger et al., 2005;
Nairz et al., 2010). As hLCN2 has potential for treatment of
infection, it is necessary to generate a recombinant hLCN2
and increase its production using animal bioreactors.
Mastitis is a devastating disease affecting dairy cattle
worldwide. It is an inflammation of the mammary gland
(Sharma et al., 2007) that can have serious economic
repercussions (Tiwari et al., 2013). The frequent and
prolonged use of antibiotics to treat mastitis has led to
the emergence of antibiotic-resistant strains. Plasmidmediated antibacterial gene transfer is a novel method that
could aid in the prevention of mastitis and help control
its spread. The plasmid-mediated technique enables
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mammary cells to synthesize and secrete the target protein
in the udder.
The aim of the present study was to determine whether
the mammalian protein hLCN2 exhibits antibacterial
activity against bacteria that cause bovine mastitis. Hence,
a mammalian-specific recombinant pIRES2-AcGFP1hLCN2 vector was constructed and introduced into stable
bovine mammary gland epithelial cell lines. Because hLCN2
has 67% sequence similarity with bovine LCN2, it may be
used as a model to understand the molecular pathways
related to innate immune defense in human beings.
Therefore, bovine udders may be used as nongeneticallymodified organism (non-GMO) bioreactors to produce
hLCN2.
Foreign gene transfer via embryonic stem cell
(McLaren, 1992) has been unsuccessful in species
other than mouse, as cells cannot be generated reliably.
Transgenic animals provide an alternative approach to
produce hLCN2 in large quantities at relatively low cost,
and animal mammary gland bioreactors are feasible
tools for the large-scale production of hLCN2. However,
it is vital to construct an efficient and specific expression
vector in order to produce hLCN2 in a mammary gland
bioreactor.
Characteristics of mammary gland development such
as growth, tissue remodeling, lactation, and involution
make the mammary gland one of the most dynamic
organs in mammals. Milk is considered the best biological
fluid medium for producing recombinant proteins from
animals. In addition, the lactation capacity of some
domestic mammalian species that are widely used for
commercial milk production, such as cows, exceeds
the nutritional needs of their offspring. Therefore, their
mammary glands are potent bioreactors that can be used
to produce valuable biologically active proteins.
2. Materials and methods
2.1. Bacterial strains, plasmids, and growth conditions
Plasmid cloning vector pIRES2-AcGFP1 was procured
from Clontech, USA. Escherichia coli DH5α strain was
used as the maintenance host for the propagation of the
plasmid. E. coli DH5α was grown in Luria–Bertani broth
aerobically at 37 °C. Agar plates were prepared by adding
1.5% (w/v) agar to the liquid medium. E. coli transformants
were selected on Luria–Bertani plates containing 50 µg/
mL kanamycin (Sigma, USA).
2.2. Synthesis and isolation of hLCN2 gene
The 720-bp full-length hLCN2 (GenBank accession no.:
NM_005564) was commercially constructed and cloned
into the pUC57 plasmid. Then hLCN2 was detected using
quantitative polymerase chain reaction (qPCR) primers
(132 bp) that were each 20-mer oligonucleotides (forward:
5′-TAG CGC TAC CGG ACTC AGAT-3′ and reverse: 5′-
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AGG AGA CCT AGG GGC ATGAT-3′). The supplied
vector was linearized using BamHI restriction enzyme, and
the targeted gene was isolated by using cloning primers.
The cloning primers (sense: 5′-ATG AAT TCA CTC
GCC ACC TCC TCT TCC ACC CC-3′ and antisense: 5′ATG GAT CCC GGG CTG GTG CGG CAG CTG GCG
GC-3′) containing restriction sites for EcoRI and BamHI
in the forward and reverse primers, respectively, were
designed for subcloning. PCR amplification was performed
using the following program: 98 °C for 5 min followed by
32 cycles of 98 °C for 10 s, 69 °C for 30 s, 72 °C for 60 s,
and a final extension at 72 °C for 10 min. A 50-µL PCR
reaction volume was used with a 10 pmol concentration of
primers, using the Prime Taq DNA polymerase kit (Genet
Bio, Korea). PCR products were separated on a 1.2%
agarose gel and extracted by Expin Gel DNA gel extraction
kit (GeneAll Biotechnology, Korea). The amplified PCR
product (1 µg) and expression vector pIRES2-AcGFP1 (1
µg) were digested with 1 µL (20 U/µL) of the restriction
enzymes EcoRI and BamHI. Two microliters of EZ-One
buffer were added in a total reaction volume of 20 µL,
incubated at 37 °C for 15 min, followed by inactivation at
65 °C for 20 min. The samples that were ready for ligation
were stored at –20 °C.
2.3. Preparation of expression constructs for mammalianspecific expression vector pIRES2-AcGFP1
The strategy for the construction of the mammalianspecific expression vector pIRES2-AcGFP1 harboring
recombinant hLCN2 is shown in Figure 1. The plasmid
expressing hLCN2 was constructed by cloning the fulllength hLCN2 into the pIRES2-AcGFP1 expression vector
(Clontech, USA). The ligation reactions were performed
using a T4 DNA ligation kit (Enzynomics, Korea). The
digested PCR products (hLCN2) were added to the
vector pIRES2-AcGFP1 in a 1:3 molar ratio for ligation
at the EcoRI and BamHI sites after the cytomegalovirus
promoter. The reaction mixture was incubated overnight
(12 h) at 16 °C with 1 µL of T4 DNA ligase enzyme (400
U/µL). The reaction was stopped by incubating at 60 °C
for 20 min, and the ligation mixture was immediately
transformed into E. coli DH5α with 50 µg/mL kanamycin
as the selection marker. After 12–13 h of incubation at
37 °C, a single colony was selected and grown in 3 mL of
broth at 37 °C for 8 h. The positive transformants were
selected by PCR screening.
The plasmid with the gene designated pIRES2AcGFP1-hLCN2 (Figure 1) was subjected to ligation
confirmation by single and double digestion. The clone
(pIRES2-AcGFP1-hLCN2) was further confirmed by
DNA sequencing (Cosmo Genetech, Korea). Furthermore,
1 µg of the recombinant material was subjected to single
digestion with 1 µL of 4 U/µL StuI enzyme and 2 µL of EZOne buffer in a total 20-µL reaction volume, then incubated
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Figure 1. Schematic representation of molecular cloning of recombinant pIRES2-AcGFP1-hLCN2 vector. (A) Isolation of hLCN2 from
pUC57 plasmid containing hLCN2 by double digestion with EcoRI and BamHI restriction enzymes; (B) targeted plasmid pIRES2AcGFP1 cloning vector map to construct recombinant vector; (C) recombinant pIRES2-AcGFP1-hLCN2 vector (6045 bp).
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at 37 °C for 15 min followed by inactivation at 65 °C for
20 min. The ligation of insert was also confirmed by using
hLCN2 qPCR primers (132 bp) that were each 20-mer
oligonucleotides (forward: 5′-TAG CGC TAC CGG ACT
CAGAT-3′ and reverse: 5′-AGG AGA CCT AGG GGC
ATG AT-3′). The PCR amplification was performed in an
Eppendorf Mastercycler using the following program: 94
°C for 5 min followed by 35 cycles of 94 °C for 30 s, 58.5
°C for 30 s, and 72 °C for 60 s, and final extension at 72 °C
for 5 min.
The
endotoxin-free,
linearized,
recombinant
pIRES2-AcGFP1-hLCN2 was subsequently used for
transfection into the bovine mammary epithelial stem
cells. Linearization was performed using StaI enzyme
(Economics, Korea).
2.4. Generation of stable transfectants with hLCN2
Bovine mammary epithelial stem cells (bMESCs) were
collected from Korean Holstein cows and maintained
in a tissue culture flask in Dulbecco’s modified Eagle’s
medium/F12 (DMEM/F12) supplemented with 10% fetal
bovine serum, 5 µg/mL of insulin, 10 ng/mL epidermal
growth factor, 10 ng/mL basic fibroblast growth factor, 100
unit/mL penicillin, 100 µg/mL streptomycin, 100 µg/mL
gentamicin, and 2.5 µg/mL amphotericin B with a seeding
rate of 1 × 105/25 cm2 (4000 cells/cm2).
When the bMESCs reached approximately 90%
confluence they were subcultured for 2–3 days before
transfection, and fresh medium was added 24 h before
transfection. Trypsinized 80% confluent cultured cells
were washed two times with phosphate buffer saline (PBS,
pH 7). Next, 1–2 ´ 106 cells were transfected with linearized
pIRES2-AcGFP1-hLCN2 plasmid (10 µg) using an
Amaxa human mammary epithelial cells nucleofector kit,
following the supplied protocol with some modifications.
Nucleofection was performed using the U-029 program
of the Amaxa Nucleofector-II machine. For the positive
control, 5 µg of pmax green fluorescent protein (GFP)
vector (Lonza, Amaxa) containing GFP was used. It
is very difficult to transfect bMESCs; hence, dimethyl
sulfoxide (DMSO; Sigma, USA) was used at an optimized
concentration of 1.6% in the transfection reagent and for
24 h after pulse. After nucleofection, cells were cultured
in the DME/F12 growth medium supplemented with 20%
fetal bovine serum. After 48 h of transfection, cells were
incubated with 250 µg/mL G418 antibiotic for 2 weeks.
Pure, stable cell lines were stored for further analysis.
2.5. Detection of hLCN2 protein in bovine mammary
epithelial stable cell lines by immunocytochemistry
Transfected bMESCs were seeded in 24-well plates and
were used for immunostaining at 60% confluence. Cells
were fixed in 4% paraformaldehyde for 30 min at 4 °C, then
treated with 0.2% Triton X-100 for 30 min at 4 °C, followed
by treatment with 0.3% H2O2 for 10 min to stop endogenous
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peroxidase activity. To prevent nonspecific binding, cells
were incubated with 10% goat serum for 1 h at 4 °C.
After they were washed 3 times with PBS, the cells were
subjected to immunostaining with rabbit polyclonal antiLipocalin-2 (Abcam, UK) primary antibody supplemented
at a dilution of 1:100 and incubated overnight at 4 °C in the
dark. For visualization, fluorescent secondary antibodies
for goat anti-rabbit conjugated with phycoerythrin (PE;
Santa Cruz, CA, USA) were added at a dilution of 1:100. To
visualize nuclei, the cells were counterstained with 0.3 µg/
mL 4,6-diamidino-2-phenylindole (DAPI) (Sigma, USA)
for 10 min. Immunostained cells were observed under a
fluorescence microscope (Olympus, Japan).
2.6. Expression analysis of hLCN2 by reverse
transcription-PCR
To confirm the insertion of hLCN2 into the transfectant
(bMESCs), total RNA from transfected cells was extracted
using the easy-BLUE total RNA extraction kit (Intron
Biotechnology, Korea). First-strand DNA synthesis was
performed using 1 µg of RNA in a 20-µL reaction volume
using the SuperScript III First-Strand Synthesis system
(Invitrogen, USA). The reaction mixture was incubated
for 50 min at 50 °C then immediately transferred to ice,
followed by inactivation of the RTase at 85 °C for 5 min,
and in the final step it was treated with RNAse for 20
min at 37 °C. All incubation and RT-PCR reactions were
performed in the Eppendorf Mastercycler (Eppendorf,
USA). First-strand DNA was used as the RT-PCR template
with the following RT-PCR program: initial heating at 94
°C for 5 min followed by 35 cycles of denaturation at 94
°C for 30 s, 58.5 °C for 30 s, and extension at 72 °C for 60
s, followed by a final extension step for 5 min at 72 °C.
The hLCN2 primer concentration was 10 pmol (forward:
5′-TAG CGC TAC CGG ACT CAG AT-3′ and reverse: 5′AGG AGA CCT AGG GGC ATG AT-3′) in a total 50-µL
PCR reaction.
2.7. Quantitation of hLCN2 secreted by transfectants
The transfected and nontransfected bMESCs (1 × 105
cells/well) were cultured in growth medium (DMEM/
F12) contained in 24-well plates. The cells and media from
both the transfected and nontransfected cell cultures were
harvested after specific intervals (i.e. on the first, second,
and fourth days of culture), and hLCN2 concentrations
in the cells and medium were determined using the
Quantikine Human Lipocalin-2/NGAL immunoassay kit
(R & D Systems, USA). The cells were lysed in dilution buffer
(PBS, 1% Triton X-100, and 1% BSA) before the ELISA
measurements (Cowland et al., 2003). Nontransfected
cells and culture media were used as controls.
2.8. Bacterial isolates and antibacterial activity of hLCN2
Two bacteria species that cause bovine mastitis,
Staphylococcus aureus and Escherichia coli, were isolated
directly from clinical cases of bovine mastitis using
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standard protocols for isolation and characterization
of these species. After the species were confirmed, the
antibacterial activity of hLCN2 against both bacteria was
evaluated by various antimicrobial assays. To test the
antimicrobial activity of recombinant hLCN2, fetal bovine
serum and antibiotic-free media from the recombinant
pIRES2-AcGFP1-hLCN2 transfected bMESCs were
analyzed for antimicrobial activity by different assays. All
tests were conducted in triplicate, and results are expressed
as mean ± standard deviation.
2.8.1. Agar-well diffusion assay
The antimicrobial activity of recombinant hLCN2 was
determined by broth microtiter dilution assay and agar
plate and agar-well diffusion assays (Cappuccinno and
Sherman, 1999; Espitia et al., 2013). S. aureus and E.
coli were grown in brain heart infusion (BHI) broth and
incubated for 24 h at 37 °C. A 100-µL aliquot of bacterial
suspension containing 1 × 105 cfu/mL of each bacterium
was spread over Mueller–Hinton agar plates containing
10-mm wells, which were filled with 100 µL of media
from transfected cells. Penicillin–streptomycin (100 µg/
mL) was used as the positive control for S. aureus, and
gentamicin (50 µg/mL) was used for E. coli. Media from
nontransfected cells were used as negative controls in both
the assays. Petri dishes containing test samples inoculated
with the bacterium were incubated at 37 °C for 24 h. The
antibacterial activity was determined by measuring the
diameter of the zone of inhibition (in millimeters) around
each well. A zone of inhibition with a diameter ≤10 mm
indicated resistant bacteria (Johnson and Case, 1995).
2.8.2. Agar plate assay
Antibacterial activity of recombinant hLCN2 was also
confirmed by the agar plating method. First, 1 × 105 cfu/
mL of bacteria (S. aureus and E. coli) were incubated in
BHI broth treated with nondiluted or 1:2 diluted media
from recombinant pIRES2-AcGFP1-hLCN2 transfected
cells or nontransfected cells and incubated for 24 h at
37 °C. Next, 100 µL of suspension from each tube was
spread over Mueller–Hinton agar and incubated for 15–16
h, and the resulting colonies were counted. Penicillin–
streptomycin (100 µg/mL) and gentamicin (50 µg/mL)
were used as positive controls for S. aureus and E. coli,
respectively, while media from nontransfected bMESCs
were used as negative controls in both assays.
2.8.3. Kinetic study of the antimicrobial activity of
hLCN2
A kinetic study of the antimicrobial activity of recombinant
hLCN2 against major bovine mastitis-causing bacteria was
conducted by broth microwell assay, following the protocol
described by Lourenco and Pinto (2001) with some
modifications. The wells in a 96-well plate were inoculated
with 100 µL containing ~1 × 105 cfu of S. aureus and E. coli
bacteria and media from transfected and nontransfected

bMESCs, followed by incubation at 37 °C for 24 h in BHI
broth. The plates were analyzed for turbidity by measuring
the optical density at 595 nm using a microplate reader
(Model-680, Bio-Rad). Penicillin–streptomycin (100 µg/
mL) and gentamicin (50 µg/mL) were used as positive
controls for S. aureus and E. coli, respectively, while media
from nontransfected cells were used as negative controls
in both assays.
2.9. Statistical analysis
All experiments were performed in triplicate, and data
were analyzed using SPSS. The results are reported as mean
± standard deviation. P values <0.05 were considered
significant.
3. Results
3.1. Construction of hLCN2 mammalian cell expression
vector pIRES2-AcGFP1
A recombinant pIRES2-AcGFP1-hLCN2 plasmid
containing two mammalian expression cassettes was
constructed as described in the methods section. GFP
expression was visually detected as early as 8–10 h after
nucleofection. As shown in Figure 2a, the pUC57 vector
containing hLCN2 was identified using the hLCN2
detection primer (132 bp). The synthetic gene fragment
of hLCN2 (720 bp) was amplified and detected by agarose
gel electrophoresis on 1.5% agarose gel (Figure 2b). The
mammalian expression vector pIRES2-AcGFP1 was
digested with restriction enzymes EcoRI and BamHI. The
amplified fragment of synthetic gene was ligated into the
pIRES2-AcGFP1 vector. The recombinant fragment was
called pIRES2-AcGFP1-hLCN2. The gene products were
obtained by restriction digestion to confirm that the gene
fragments were present in the vector that was used for
transfection into bMESCs (Figure 2c). The incorporation
of the gene into the vector was confirmed by RT-PCR
amplification of the gene fragments from the recombinant
plasmid, using specific forward and reverse primers for the
respective genes (Figure S1). Thus, we confirmed that the
gene fragment was successfully inserted into the pIRES2AcGFP1 vector.
The quality of the recombinant plasmid was confirmed
by DNA sequencing, and the clone was evaluated using a
sequencing chromatogram. The result was observed using
Finch TV software, and the sequence was evaluated again
by BLASTn (Figure S2). The sequence data showed 100%
similarity to the original gene sequence (accession no.:
NM_005564) with the hLCN2 insert (720 bp). Hence, the
clone produced was high in quality.
3.2. Establishment of hLCN2-transfected bovine
mammary epithelial stable cell lines
To produce stable cell lines, we transduced the bMESCs
with the Amaxa nucleofection method using the
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Figure 2. PCR detection and amplification of hLCN2 in pUC57 vector and confirmation of hLCN2 ligation in the recombinant pIRES2AcGFP1-hLCN2 plasmid.
(A) PCR detection of hLCN2 in the pUC57 vector with qPCR primer.
Lane M1: 1-kb DNA ladder; lane 1: pUC57 vector with hLCN2 gene; lane 2: PCR-detected hLCN2 (132 bp); lane M2: 100-bp DNA ladder.
(B) PCR amplification of hLCN2 from pUC57 vector using cloning primer.
Lane M: 100-bp DNA ladder; lane 2: PCR-amplified hLCN2 (720 bp).
(C) Confirmation of hLCN2 ligation in the recombinant pIRES2-AcGFP1-hLCN2 plasmid by restriction enzymes.
Lane M1: 1-kb DNA marker; lane 1: undigested recombinant pIRES2-AcGFP1-hLCN2 plasmid; lane 2: single digestion of recombinant
pIRES2-AcGFP1-hLCN2 plasmid with BamHI; lane 3: double digestion of recombinant pIRES2-AcGFP1-hLCN2 plasmid with BamHI
and EcoRI; lane M2: 100-bp DNA marker.

recombinant pIRES2-AcGFP1-hLCN2 plasmid. Pmax
green fluorescent protein (GFP; Lonza, USA) was used
as a positive control and showed an approximately
30%–35% transfection rate (Figure 3a). The recombinant
pIRES2-AcGFP1-hLCN2 plasmid was expressed at 48 h
posttransfection with 15%–20% transfection efficiency
in bMESCs (Figures 3b and 3c). However, weak GFP
expression was observed after 8–10 h of transfection.
These results indicated that the recombinant plasmid
was successfully transfected into host cells. After 48 h of
transfection, cells were subjected to selection with 250 µg/
mL of neomycin (G418), and within 2 weeks pure colonies
were obtained (Figure 3d). Neomycin-resistant cells were
selected and transferred to fresh selection medium where
they multiplied, finally producing recombinant hLCN2transfected purified cells. The results demonstrate that
pIRES2-AcGFP1 is a powerful tool for transfection of
mammalian cells, particularly bovine mammary epithelial
cells. The purified transfected cells were used for further
analysis and determination of hLCN2 production.
3.3. Analysis of hLCN2 expression in the transfected cells
using RT-PCR
After the pure and stable recombinant transfected
bMESCs were obtained, an hLCN2 mRNA expression
study further confirmed the integration of the target
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insert. Strong expression of hLCN2 (132 bp) was observed
in the transfected stable cell lines (Figure 4), while
nontransfected bMESCs were used as negative control.
These results confirmed the successful construction of a
recombinant plasmid and its integration into bMESCs.
3.4. Potential of transfected bMESCs to produce
recombinant hLCN2
To study the production of hLCN2 by transfected bMESCs,
the concentration of hLCN2 in both the cell lysate and cell
culture medium was analyzed at different time points.
Nontransfected cells served as the negative control. We
cultured 1 × 105 bMESCs per well and found 22 ± 2.52 ng
of hLCN2 in the cell lysate after 1 day of culture (Figure
5a). The same number of cells secreted 6.85 ± 0.11 µg
of hLCN2 into the medium over a 1-day period (Figure
5b), an amount 300-fold higher than the value of hLCN2
stored within the cells. These results indicate that hLCN2
is transported out of the cell by constitutive secretion.
Meanwhile, hLCN2 was not detected in the nontransfected
cell lysate or the medium of the control cells (Figures 5a
and 5b). The quantity of hLCN2 stored within the cells
increased (although not significantly) during culture,
perhaps due to the increase in the number of cells from
the initial 1 ´ 105 to 4 × 105 ± 3.93 on the fourth day. The
production of hLCN2 in the media also increased with
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Figure 3. Transfection, expression, and establishment of bovine mammary epithelial stable cell lines with recombinant pIRES2-AcGFP1hLCN2. (A) Expression of Pmax GFP (positive control) after 48 h of transfection (100×); (B) phase contrast image of recombinant
pIRES2-AcGFP1-hLCN2 after 48 h of transfection (100×); (C) green fluorescence expression of recombinant pIRES2-AcGFP1-hLCN2
after 48 h of transfection; (D) purified recombinant hLCN2 (pIRES2-AcGFP1-hLCN2) cell lines after 2 weeks of transfection in
neomycin (250 µg/mL), used as selection marker (100×). Cells showed normal proliferation rate; bovine mammary epithelial stem cells
showed normal morphology, nuclei, and cytoplasm ratio.
1

M

2

132 bp

Figure 4. Expression analysis of hLCN2 in bMESCs by RT-PCR.
Lane M: 100-bp DNA marker.
Lane 1: Expression of hLCN2 mRNA in the bMESCs transfected with recombinant pIRES2-AcGFP1-hLCN2.
Lane 2: Nontransfected bMESCs did not show expression of hLCN2.
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Figure 5. Determination of hLCN2 production by bovine mammary epithelial stem cells (bMESCs) at different time points. Both
transfected and nontransfected cells were seeded at a concentration of 1 × 105 cells/well in 24-well plates. Cell numbers reached 1.5 × 105
± 1.42, 1.8 × 105 ± 2.63, and 4 × 105 ± 3.93 cells on the first, second, and fourth days of culture, respectively. (A) hLCN2 concentration
was measured in the recombinant pIRES2-AcGFP1-hLCN2 that was transfected and in nontransfected bMESC lysate on the first,
second, and fourth days of culture. (B) Production of hLCN2 in the media by recombinant pIRES2-AcGFP1-hLCN2 transfected cells at
different time points with the same number of cells as previously described. Nontransfected bMESCs were used as control.

time and was 350-fold higher than the amount of hLCN2
stored within the cells after 4 days of culture with the same
number of cells (4 × 105 ± 3.93). These results suggest that
the recombinant cells into which pIRES2-AcGFP1-hLCN2
was transfected may potentially be used as a source of
hLCN2.
3.5. Determining hLCN2 expression in the stable cell
lines using immunocytochemistry
The purified colonies of hLCN2-transfected cells were
subjected to immunochemical analysis to further confirm
cloning and transfection. Red signals of phycoerythrin
fluorescence (Figure 6a) obtained after staining with
primary rabbit polyclonal anti-Lipocalin-2 confirmed
that hLCN2 was successfully cloned and transfected into
bMESCs. Figure 6b shows green fluorescence signals but
no staining with primary antibodies in the clone. These
results further confirmed the successful cloning of hLCN2
and the potential of pIRES2-AcgFP to express the insert
in transfected bMESCs. These results also indicate the
location of recombinant hLCN2 in the bMESCs.
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3.6. Antibacterial activity of recombinant hLCN2
Previous studies reported that LCN2 possesses strong
antibacterial and antiinflammatory properties (Hammer
and Skaar, 2011; Robinson et al., 2014). Hence,
antimicrobial assays were performed to evaluate the
antibacterial activity of hLCN2 against major pathogens
causing bovine mastitis. Results from these antibacterial
assays, which were conducted by agar-well diffusion assay,
are shown in Figure 7. We found that hLCN2 inhibited the
growth of E. coli more strongly than it inhibited S. aureus.
The diameter of the zone of inhibition resulting from
hLCN2 activity against E. coli was 32.0 ± 0.98 mm (Figure
7a, B), and for the standard antibiotic positive control it
was 38.5 ± 1.2 mm (Figure 7b, B). The diameter of the
zone of inhibition against S. aureus was 22.02 ± 0.08 mm
(Figure 7a, A), and for the standard antibiotic control it
was 46.18 ± 0.18 mm (Figure 7b, A). Inhibition of bacterial
growth was not observed for the negative control PBS or
media from nontransfected cells (Figures 7c, 7d; A, B).
A kinetic study of the antimicrobial activity of
recombinant hLCN2 was performed by broth microwell
assay, and bacterial growth was determined at different
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Figure 6. Confirmation of successful integration of recombinant hLCN2 into bovine mammary epithelial stem cells (bMESCs) by
immunochemical detection.
(A) bMESCs transfected with recombinant pIRES2-AcGFP1-hLCN2 showing red ﬂuorescence after immunostaining with primary
rabbit polyclonal anti-Lipocalin-2 and goat anti-rabbit secondary antibody conjugated with phycoerythrin (PE) (a), 4, 6-diamidino-2phenylindole (DAPI) nuclear staining (a’), and merged (a”) (100×).
(B) bMESCs transfected with recombinant pIRES2-AcGFP1-hLCN2 and immunostained without primary antibody (control), showing
only green signal fluorescence of recombinant hLCN2, while no signals of goat anti-rabbit secondary antibody conjugated with
phycoerythrin (PE) are observed (b), DAPI nuclear staining (b’), and merged (b”) (200×).
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d
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Figure 7. Evaluation of antibacterial activity of recombinant hLCN2 against bovine mastitis, causing gram-positive and gram-negative
bacteria by agar-well diffusion assay. Plates show antibacterial activity of hLCN2 secreted by transfected bMESCs (a) against mastitiscausing bacteria S. aureus (A) and E. coli (B). A strong zone of inhibition is observed for penicillin–streptomycin (100 µg/mL) or
gentamicin (50 µg/mL) as positive control (b); no zone of inhibition is observed with media from nontransfected cells (c) and normal
saline (d), the negative controls.
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4. Discussion
To our knowledge, this is the first study in which pIRES2AcGFP1 containing hLCN2 was expressed in cattle
mammary epithelial cells that were then used as bioreactors
to produce the antibacterial protein hLCN2. For the past
several decades, research has focused on investigating
novel antimicrobial agents to control challenging diseases,
including bovine mastitis. Numerous antimicrobial
peptides and proteins, most of which are components
of the acute innate immune response to infection, have
been tested for clinical applications. The production of
these proteins is induced by pattern recognition receptors,
as well as cytokines of the innate and acquired immune
pathways, that play important roles in infection control
and immunomodulatory homeostasis (Chan et al., 2009).
Lipocalin 2, also known as neutrophil gelatinaseassociated lipocalin (NGAL), siderocalin, or uterocalin,
is a 25-kDa protein that belongs to the lipocalin protein
family (Kjeldsen et al., 2000). It exhibits antimicrobial
activity by sequestering iron and improves host defense
against pathogens, such as E. coli (Flo et al., 2004; Hammer
and Skaar, 2011) and S. aureus (Robinson et al., 2014).
The LCN2 gene is highly expressed in various epithelial
tissues (Cowland and Borregaard, 1997). Previous studies
suggested that NGAL is upregulated in response to
hLCN2
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inflammation
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Change in absorbance (595 nm)
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time points. Data obtained from these assays indicated
that hLCN2 has strong antibacterial activity against both
S. aureus (Figure 8a) and E. coli (Figure 8b). Absorbance
values obtained for the hLCN2-treated group were
compared with those obtained for the group treated with
a standard antibiotic. The results clearly show strong
antibacterial activity from 4–5 h onward. Recombinant
hLCN2 antibacterial activity against E. coli was stronger
than activity against S. aureus.
The ability of hLCN2 to suppress bacterial proliferation
is one of its most important properties. Hence, the
antibacterial activity of recombinant hLCN2 against the
major mastitis-causing bacteria S. aureus (Figure 9, A)
and E. coli (Figure 9, B) was tested by agar plate method.
The presence of nondiluted media from recombinant cells
into which pIRES2-AcGFP1-hLCN2 had been transfected
significantly slowed the proliferation of both types of
bacteria (Figure 9a, A; Figure 9a, B), compared with
untreated controls (Figure 9c, A; Figure 9c, B). Antibacterial
activity of hLCN2 in a 1:2 diluted medium (Figure 9b, A
and B) was lower than activity in a nondiluted medium
(Figure 9a, A and B). hLCN2 had a stronger antibacterial
effect on E. coli than on S. aureus. After treatment with
nondiluted media from hLCN2-transformed cells, S.
aureus and E. coli grew at 366.00 ± 7.94 cfu/mL and 51.00
± 3.60 cfu/mL, respectively, with significantly higher cell
densities (P < 0.05) in the 1:2 diluted media-treated groups
for both S. aureus (1814 ± 13.05 cfu/mL) and E. coli (917
± 15.72 cfu/mL). Inhibition of bacterial proliferation was
observed from 4 h onward. Thus, the results obtained from
different antibacterial assays clearly indicate that hLCN2
exhibits antibacterial activity against major mastitiscausing pathogens and can be used as an antimicrobial
agent to manage bovine mastitis.
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Figure 8. Evaluation of the antibacterial activity of hLCN2 against mastitis-causing bacteria by microdilution assay. Optical density was
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Figure 9. Inhibitory activity of recombinant hLCN2 against bovine mastitis-causing bacteria (S. aureus/E. coli). Nondiluted and 1:2
diluted media from recombinant pIRES2-AcGFP1-hLCN2 transfected cells or nontransfected cells were incubated for 24 h with 1 × 105
cfu/mL bacteria (S. aureus/E. coli) in BHI broth. A 100-µL aliquot of suspension from each tube was spread over Mueller–Hinton agar
and incubated for 15–16 h.
(A) S. aureus bacteria cultured from bovine mastitis cases. (a) Few bacterial colonies are seen on nondiluted media; (b) approximately
twice as many bacterial colonies are seen on 1:2 diluted media compared to nondiluted media; (c) confluent bacterial growth is seen
on media from nontransfected cells (negative control); and (d) no bacterial growth is observed upon addition of standard antibiotic
penicillin–streptomycin (100 µg/mL) to S. aureus culture (positive control).
(B) E. coli bacteria cultured from bovine mastitis samples. (a) Few bacterial colonies are seen on nondiluted media; (b) approximately
twice as many bacterial colonies are seen on 1:2 diluted media compared to nondiluted media; (c) media from nontransfected cells
showing confluent growth of bacteria (negative control); and (d) no bacteria growth is seen upon addition of standard antibiotic
gentamicin (50 µg/mL) to E. coli culture (positive control).

RT-PCR. Strong GFP expression and immunochemistry
results showed that the gene had been successfully
integrated into the genome of the transgenic cells and was
expressed at a high level. Indeed, GFP-positive cells could
be detected 8 to 10 h after transfection of bMESCs with the
Amaxa human mammary epithelial cell nucleofector kit.
No obvious toxic effects on host cells were detected after
microscopic examination of transduced bovine mammary
epithelial stem cells. However, the efficiency of transfection
was very low, even after 48 h of transfection (Figure 3).
Robust and regulated protein production in
mammalian epithelial cells requires careful consideration
of many factors, such as the process of translation,
insertion of the gene into the chromosome, and the toxic
effect on the host cell. Transient gene expression is used to
rapidly produce small quantities of proteins of interest for
initial characterization and to test vector functionality. In
contrast, preparation of stable cell lines requires integration
of the plasmid into the host chromosome.
pIRES2-AcGFP1 contains multiple cloning sites
and an internal ribosomal entry site (IRES) for the

encephalomyocarditis virus, followed by GFP of
Aequorea coerulescens (Figure 1). This approach allows
the bicistronic expression of the gene of interest and the
marker proteins GFP. IRES-driven translation initiation
was first demonstrated for picornavirus (Jang et al., 1988),
which can recruit ribosomes directly to initiate translation
using a 5′-end independent method. IRESs are commonly
used to direct the expression of the downstream cistrons
of bicistronic or oligocistronic mRNAs. The human
cytomegalovirus promoter ensures that the gene of
interest is highly expressed. pIRES2-AcGFP1 harbors a
neomycin-resistance gene that allows stable transfection of
mammalian cells, followed by selection with the antibiotic
G418. Expression of the resistance gene is controlled by
the SV40 early promoter. The presence of a pUC origin
of replication allows replication and growth in E. coli, and
the kanamycin-resistance gene enables selection of the
plasmid in E. coli (Thalhamer, 2009).
Our results suggest that pIRES2-AcGFP1 is an efficient
vector to carry hLCN2 and transfer the gene into bMESCs.
pIRES2-AcGFP1 has been used as an efficient vector for
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various cell lines, such as HeLa cells and NCI-H295R cells
(Thalhamer, 2009; Armacki, 2010; de Souza, 2011).
DMSO enhances the uptake of DNA by augmenting
the permeability of the cell membrane and reducing
osmotic shock (Kawai and Nishizawa, 1984). The DMSO
concentration required for efficient transfection varies
from cell to cell. In fact, the concentration of DMSO
that is optimal for one cell line may be toxic for another.
This finding has also been confirmed by a recent study
conducted by Hashemi et al. (2012), who observed a 60%
and 50% decrease in the electroporation efficiency and
survival rate, respectively, of Huh-7. In the present study,
we used 1.6% DMSO to enhance transfection efficiency,
whereas 2% DMSO showed more than 90% toxicity in
bMESCs. Melkonyan et al. (1996) recommended 1.25%
DMSO for high transfection efficiency of mammalian
cells.
A recent report by Maurisse et al. (2010) indicated
that electroporation or nucleofection were superior to
chemical methods for the delivery of DNA into primary
and transformed mammalian cells. Like those of Maurisse
et al. (2010), our results showed that electrotransfection
was the best method for use with primary bovine
mammary epithelial stem cells. This method resulted in
the successful generation of the pIRES2-AcGFP1-hLCN2
transduced stable bovine mammary epithelial stem cells in
the present study.
In order to produce a novel antibacterial protein,
a recombinant pIRES2-AcGFP1-hLCN2 vector was
designed. The gene was inserted between the BamHI and
EcoRI sites, and the recombinant expression vector for
the heterologous expression of pIRES2-AcGFP1-hLCN2
in E. coli DH5α was obtained. Recombinant hLCN2 was
subjected to antibacterial assays to determine its activity
against major bovine-mastitis–causing organisms. Data
obtained from antimicrobial activity assays, conducted
by broth microwell, agar plate, and agar-well diffusion
methods, confirmed that hLCN2 showed potent
antibacterial activity against S. aureus and E. coli bacteria.
LCN2 prevents the growth of bacteria that rely on
catechol-type siderophores for iron acquisition (Flo et al.,
2004). Siderophores are small iron-chelator molecules that
are produced both by E. coli (Bnyan et al., 2010) and S.
aureus (Dale et al., 2004; Hammer and Skaar, 2011) and
are essential for bacterial survival and virulence (Dale
et al., 2004). Many gram-negative outer-membrane
transporters and gram-positive lipoprotein siderophorebinding proteins have been characterized, and their
binding abilities with outer-membrane transporters and
siderophore-binding proteins for Fe-siderophores have
been determined (Fukushima et al., 2013). Dale et al.
(2004) identified and characterized a nine-gene ironregulated operon, designated sbn, that is situated between
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sirABC and galE on the S. aureus chromosome and that is
involved in the production of a siderophore.
Vertebrates sequester excess iron within proteins
in order to alleviate toxicity and restrict the amount of
free iron available for invading pathogens. Restricting
the growth of infection-causing microorganisms by
sequestering essential nutrients is referred to as nutritional
immunity (Hammer and Skaar, 2011). LCN2 binds
catecholate-type siderophores such as enterobactin (made
by E. coli). LCN2 can arrest E. coli growth by depriving
bacteria of iron, which distinguishes LCN2’s mode of
action from the conventional pore-forming mechanisms
of cationic antimicrobial peptides (Chan et al., 2010). Our
results agree with those of Chan et al. (2010). We observed
higher antibacterial activity against E. coli than against
S. aureus isolates, which may be due to the greater iron
requirements of E. coli.
Immune system cells produce LCN2, which scavenges
the E. coli siderophore-iron complex, thereby preventing
iron uptake in bacteria such as E. coli (Flo et al., 2004) and S.
aureus (Robinson et al., 2014). This activity inhibits E. coli
growth. Berger et al. (2005) reported that LCN2-deficient
mice exhibit increased sensitivity to E. coli infection. Flo
et al. (2004) reported that staphylococcal siderophores are
not scavenged by LCN2, and that growth of S. aureus is not
inhibited by LCN2-containing serum; however, our data
indicate that hLCN2 has antibacterial activity against E.
coli and S. aureus, conflicting with the results obtained by
Flo et al. (2004).
LCN2 protein levels in serum increase during infection
and inflammation (Kjeldsen et al., 2000; Berger et al.,
2005; Nairz et al., 2010). Hence, LCN2 has potential as
an antibacterial agent to manage bovine mastitis. The
failure of antibiotic therapy and vaccination to control
mastitis poses a major challenge. Therefore, researchers
are investigating novel options, such as plasmid-mediated
antimicrobial gene transfer to the mammary gland cells,
nutritional approaches to enhance the immunity of the
udder, and development of an antibacterial system in the
udder to fight the invading microorganisms. Zhang et al.
(2007) demonstrated the use of the plasmid-mediated
gene transfer technique to enable mammary gland cells
to synthesize and secrete bovine lactoferricin, as well as
bovine tracheal antimicrobial peptides, in order to prevent
bovine mastitis.
In conclusion, our work showed that pIRES2-AcGFP1
was an efficient vector that delivered the target gene into
the bovine mammary epithelial stem cells. Moreover, the
recombinant cells into which pIRES2-AcGFP1-hLCN2
was transfected may be used as a source of hLCN2 to
protect mammary glands from major mastitis-causing
bacteria.
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Figure S1. Confirmation of hLCN2 ligation in the recombinant pIRES2-AcGFP1-hLCN2 plasmid by PCR.
Lane M1: 1-Kb DNA marker.
Lane 1: recombinant pIRES2-AcGFP1-hLCN2 plasmid.
Lane 2: PCR product of hLCN2 (132 bp).
Lane M2: 100-bp DNA marker.
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Figure S2. Authentication of cloned amplicon by sequencing. Recombinant pIRES2-AcGFP1-hLCN2 sequencing similarity results (A)
and chromatogram (B).
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Figure S2. (Continued).
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